Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_3_presentation_3_-_plaque_psoriasis [2017/04/07 23:59] fisicosm |
group_3_presentation_3_-_plaque_psoriasis [2018/01/25 15:18] (current) |
||
|---|---|---|---|
| Line 13: | Line 13: | ||
| {{:pi1.png|}} | {{:pi1.png|}} | ||
| - | Figure: Plaque psoriasis | + | Figure 1: Plaque psoriasis |
| Image from: http://jamanetwork.com/journals/jama/fullarticle/1104805 | Image from: http://jamanetwork.com/journals/jama/fullarticle/1104805 | ||
| </style> | </style> | ||
| Line 42: | Line 42: | ||
| {{:screen_shot_2017-04-06_at_1.18.11_pm.png|}} | {{:screen_shot_2017-04-06_at_1.18.11_pm.png|}} | ||
| - | Figure: A typical psoriatic plaque | + | Figure 2: A typical psoriatic plaque |
| Image from: http://www.wikipedia.com | Image from: http://www.wikipedia.com | ||
| {{:screen_shot_2017-04-06_at_1.23.58_pm.png|}} | {{:screen_shot_2017-04-06_at_1.23.58_pm.png|}} | ||
| - | Figure: A red and scaly scalp lesion | + | Figure 3: A red and scaly scalp lesion |
| Image from: http://nopsoriasis.net | Image from: http://nopsoriasis.net | ||
| </style> | </style> | ||
| Line 77: | Line 77: | ||
| {{:screen_shot_2017-04-06_at_1.16.39_pm.png|}} | {{:screen_shot_2017-04-06_at_1.16.39_pm.png|}} | ||
| - | Figure: Ranking the severity of psoriasis, via PASI | + | Figure 4: Ranking the severity of psoriasis, via PASI |
| Image from: http://www.healthline.com | Image from: http://www.healthline.com | ||
| </style> | </style> | ||
| Line 111: | Line 111: | ||
| {{:psor_eti_.png|}} | {{:psor_eti_.png|}} | ||
| - | Figure: The genetic linkage of plaque psoriasis | + | Figure 5: The genetic linkage of plaque psoriasis |
| Image from: https://www.slideshare.net/Gurpgork/psoriasis-35245580 | Image from: https://www.slideshare.net/Gurpgork/psoriasis-35245580 | ||
| Line 137: | Line 137: | ||
| {{:patho_psor.png|}} | {{:patho_psor.png|}} | ||
| - | Figure: Cytokine networks in psoriasis | + | Figure 6: Cytokine networks in psoriasis |
| Image from: http://www.nature.com/nature/journal/v445/n7130/abs/nature05663.html | Image from: http://www.nature.com/nature/journal/v445/n7130/abs/nature05663.html | ||
| </style> | </style> | ||
| Line 196: | Line 196: | ||
| This drug is an oral retinoid, which is a synthetic form of vitamin A and usually prescribed to those with severe cases of psoriasis (Feldman, 2013). Retinoids help control the multiplication of cells, including the speed with which skin cells grow and shed, which increases in psoriasis (Mayo Clinic, 2015). The dose ranges of acitretin can be anywhere from 25 mg every other day to 50 mg daily (Feldman, 2013). Acitretin can also be prescribed in combination with UVA or PUVA therapy; shown to increase response rates (Feldman, 2013). The use of this medication may put one at risk of lip inflammation or hair loss. Those who are or may become pregnant should also be wary of this medication as it has been shown to elicit birth defects in pregnant women (Mayo Clinic, 2015). | This drug is an oral retinoid, which is a synthetic form of vitamin A and usually prescribed to those with severe cases of psoriasis (Feldman, 2013). Retinoids help control the multiplication of cells, including the speed with which skin cells grow and shed, which increases in psoriasis (Mayo Clinic, 2015). The dose ranges of acitretin can be anywhere from 25 mg every other day to 50 mg daily (Feldman, 2013). Acitretin can also be prescribed in combination with UVA or PUVA therapy; shown to increase response rates (Feldman, 2013). The use of this medication may put one at risk of lip inflammation or hair loss. Those who are or may become pregnant should also be wary of this medication as it has been shown to elicit birth defects in pregnant women (Mayo Clinic, 2015). | ||
| - | **__MANAGEMENT__** | + | **__MANAGEMENT__** |
| **Moisturizers and emollients** | **Moisturizers and emollients** | ||
